Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

SYN has been the subject of several other research reports. ValuEngine upgraded Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.92.

Shares of Synthetic Biologics (SYN) opened at $0.79 on Friday. Synthetic Biologics has a 52 week low of $0.41 and a 52 week high of $1.60.

Synthetic Biologics (NYSEMKT:SYN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.10).

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/04/bidaskclub-downgrades-synthetic-biologics-inc-syn-to-sell.html.

A number of large investors have recently modified their holdings of SYN. Bank of New York Mellon Corp lifted its stake in Synthetic Biologics by 3.1% in the 1st quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after purchasing an additional 7,962 shares during the last quarter. UBS Group AG lifted its stake in Synthetic Biologics by 10.3% in the 1st quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after purchasing an additional 20,038 shares during the last quarter. Creative Planning lifted its stake in Synthetic Biologics by 65.4% in the 2nd quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after purchasing an additional 70,000 shares during the last quarter. LMR Partners LLP acquired a new stake in Synthetic Biologics in the 2nd quarter valued at about $194,000. Finally, Goldman Sachs Group Inc. lifted its stake in Synthetic Biologics by 8,102.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after purchasing an additional 1,115,343 shares during the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.